A new CDC analysis shows US tuberculosis did not simply vanish during COVID-19; 2020 cases fell far below prediction, then rebounded above prediction by 2023, while 2024 cases rose again to 10,388. That pattern points to delayed detection, disrupted screening, and renewed exposure rather than durable elimination. The next decade will hinge less on a single medical breakthrough than on whether migration screening, primary-care detection, and sustained program funding stay intact after the pandemic shock. ([wwwnc.cdc.gov](https://wwwnc.cdc.gov/eid/article/32/3/25-1459_article))
Verdict: The evidence supports a persistent TB management problem rather than a short anomaly: CDC found 2020 cases well below prediction, 2023 above prediction, and 2024 rising again to 10,388 cases (CDC, 2026-03-10; CDC, 2025-12-19). WHO also warns that funding cuts are already weakening detection, tracing, and surveillance capacity (WHO, 2025-03-05). Confidence is medium because the trend is clear, but local program responses will vary widely. ([wwwnc.cdc.gov](https://wwwnc.cdc.gov/eid/article/32/3/25-1459_article))
Public-health leaders treat the rebound as a systems warning and rebuild screening, tracing, and treatment completion capacity. Primary care, shelters, correctional health, and migrant health programs coordinate earlier detection. Case growth slows and then resumes a long decline. ([wwwnc.cdc.gov](https://wwwnc.cdc.gov/eid/article/32/3/25-1459_article))
TB remains manageable but stubborn, with national progress masking sharper risk in specific cities and vulnerable groups. Programs improve some screening pathways yet remain financially fragile. The disease becomes a recurring test of whether public health can sustain quiet, unglamorous prevention work. ([wwwnc.cdc.gov](https://wwwnc.cdc.gov/eid/article/32/3/25-1459_article))
Funding erosion weakens labs, contact tracing, and follow-up treatment, especially where housing instability and access barriers are already severe. Delayed diagnoses create more cluster outbreaks and higher costs per case. National counts rise even if the problem stays geographically concentrated. ([wwwnc.cdc.gov](https://wwwnc.cdc.gov/eid/article/32/3/25-1459_article))
A political decision to reframe TB as a migration-only issue distorts resource allocation. Domestic detection in US-born high-risk groups and social settings then receives too little attention. Counts keep rising because the surveillance frame is narrower than the transmission reality. ([wwwnc.cdc.gov](https://wwwnc.cdc.gov/eid/article/32/3/25-1459_article))
Developments: Health agencies will use new CDC findings to justify stronger case finding and follow-up in high-risk settings. World TB Day messaging and state surveillance reviews will keep attention on service continuity and early detection. Programs with intact staffing will likely expand screening links with migrant health, shelters, and primary care. ([wwwnc.cdc.gov](https://wwwnc.cdc.gov/eid/article/32/3/25-1459_article))
Risks: Many jurisdictions still face workforce and laboratory constraints. Public attention may fade because TB rises slowly and unevenly. If funding stays unstable, new plans may exist on paper without enough field capacity. ([wwwnc.cdc.gov](https://wwwnc.cdc.gov/eid/article/32/3/25-1459_article))
Outlook: The near-term story is recognition rather than resolution. More officials will accept that the COVID-era drop partly reflected missed detection. Response quality will diverge by locality. ([wwwnc.cdc.gov](https://wwwnc.cdc.gov/eid/article/32/3/25-1459_article))
Developments: More TB control work will likely shift into ordinary primary-care and community-health workflows. Programs will prioritize latent infection treatment completion and faster referral after abnormal screening. Better linkage between arrival screening data and local follow-up could improve early diagnosis. ([wwwnc.cdc.gov](https://wwwnc.cdc.gov/eid/article/32/3/25-1459_article))
Risks: Primary-care settings may not absorb new duties well without dedicated funding and case management. Patients at highest risk often face housing, insurance, language, or stigma barriers that routine care alone does not solve. Fragmented data systems can still break follow-up after a positive screen. ([wwwnc.cdc.gov](https://wwwnc.cdc.gov/eid/article/32/3/25-1459_article))
Outlook: The control model will broaden beyond specialty clinics. Execution will matter more than guidance. Missed follow-up will remain the crucial failure point. ([wwwnc.cdc.gov](https://wwwnc.cdc.gov/eid/article/32/3/25-1459_article))
Developments: Jurisdictions that preserved lab turnaround, contact tracing, and treatment support will likely stabilize faster. Others will cycle through localized outbreaks and expensive emergency responses. Nationally, TB will look less like one trend and more like a map of uneven public-health capability. ([wwwnc.cdc.gov](https://wwwnc.cdc.gov/eid/article/32/3/25-1459_article))
Risks: Complacency can return if national counts level off briefly. High-burden groups may remain undercounted when services are mistrusted or hard to reach. Rising social vulnerability can offset technical gains in diagnostics and guidance. ([wwwnc.cdc.gov](https://wwwnc.cdc.gov/eid/article/32/3/25-1459_article))
Outlook: By year three, local capacity gaps will explain more than national averages. Strong programs will look quietly effective. Weak programs will look repeatedly surprised. ([wwwnc.cdc.gov](https://wwwnc.cdc.gov/eid/article/32/3/25-1459_article))
Developments: States and cities will increasingly use TB indicators as a test of whether public health can sustain long-horizon disease control. Better integrated data and treatment support should reduce some preventable progression from latent infection to active disease. Where services remain stable, the disease burden will concentrate more narrowly in specific social and geographic pockets. ([wwwnc.cdc.gov](https://wwwnc.cdc.gov/eid/article/32/3/25-1459_article))
Risks: Funding may continue to favor crisis response over persistent prevention. Geographic concentration can mislead leaders into thinking the threat is purely local and not systemwide. Drug resistance and delayed diagnosis could keep costs high even when total case counts are moderate. ([who.int](https://www.who.int/news/item/05-03-2025-funding-cuts-to-tuberculosis-programmes-endanger-millions-of-lives))
Outlook: Five years out, TB will expose the quality of routine public-health maintenance. Places with discipline will bend the curve. Places with unstable financing will pay more for worse outcomes. ([wwwnc.cdc.gov](https://wwwnc.cdc.gov/eid/article/32/3/25-1459_article))
Developments: A decade from now, the most likely US path is slower decline than pre-pandemic elimination hopes once assumed. Control will depend on sustained screening of high-risk groups, better completion of preventive therapy, and durable community outreach. If that infrastructure holds, national incidence can edge down even while importation and concentrated outbreaks continue. ([wwwnc.cdc.gov](https://wwwnc.cdc.gov/eid/article/32/3/25-1459_article))
Risks: If financing repeatedly breaks, the country could settle into a high-cost plateau. Social fragmentation and uneven access may keep transmission alive in overlooked settings. Policy overfocus on borders could miss domestic reservoirs and delay control. ([wwwnc.cdc.gov](https://wwwnc.cdc.gov/eid/article/32/3/25-1459_article))
Outlook: Ten years is enough to see whether the post-COVID reset was temporary or structural. The probable answer is mixed progress, not elimination. TB will reward boring competence more than breakthrough headlines. ([wwwnc.cdc.gov](https://wwwnc.cdc.gov/eid/article/32/3/25-1459_article))
Developments: Two decades out, US TB is likely to be more concentrated in identifiable high-risk networks and settings if routine screening improves. That would make targeted control more feasible and more politically vulnerable, because the problem would feel distant from most voters. The strongest systems will maintain low incidence through steady outreach, treatment support, and surveillance discipline. ([wwwnc.cdc.gov](https://wwwnc.cdc.gov/eid/article/32/3/25-1459_article))
Risks: Long-run neglect is common when visible crisis fades. Global funding shocks and migration disruptions can still reshape local risk quickly. Persistent stigma may keep affected communities outside formal care pathways. ([who.int](https://www.who.int/news/item/05-03-2025-funding-cuts-to-tuberculosis-programmes-endanger-millions-of-lives))
Outlook: The long horizon favors concentration rather than disappearance. That makes good control technically easier and politically harder. Sustained attention will be the scarce resource. ([wwwnc.cdc.gov](https://wwwnc.cdc.gov/eid/article/32/3/25-1459_article))
Developments: Fifty years out, TB could be rare in the United States if screening, treatment completion, and social support remain durable across generations. Just as plausibly, it could persist as a chronic inequity marker affecting marginalized groups that public systems never fully reach. The decisive variable is not whether TB is scientifically understood, but whether institutions keep doing the labor of prevention. ([wwwnc.cdc.gov](https://wwwnc.cdc.gov/eid/article/32/3/25-1459_article))
Risks: Prevention systems are easiest to cut when they seem successful. Cross-border and global disruptions can reintroduce pressure faster than weak systems can recover. The greatest long-run risk is normalized underinvestment disguised as targeted efficiency. ([who.int](https://www.who.int/news/item/05-03-2025-funding-cuts-to-tuberculosis-programmes-endanger-millions-of-lives))
Outlook: The function of TB as a stress test will outlast the current rebound. Elimination is possible but not automatic. Institutional stamina is the core forecast variable. ([wwwnc.cdc.gov](https://wwwnc.cdc.gov/eid/article/32/3/25-1459_article))